Noninvasive Serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort

Clinical Infectious Diseases

Volumn 57, Issue 2, 2013, Pages 240-246

  Holmberg, Scott D ^a   Lu, Mei ^b   Rupp, Loralee B ^c   Lamerato, Lois E ^c   Moorman, Anne C ^a   Vijayadeva, Vinutha ^d   Boscarino, Joseph A ^e   Henkle, Emily M ^f   Gordon, Stuart C ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Data Coordinating Center   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d KAISER PERMANENTE   (United States)

^e GEISINGER HEALTH SYSTEM   (United States)

^f CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

chronic hepatitis; clinical staging; hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING; STAGING; THROMBOCYTE; THROMBOCYTE COUNT;

CHRONIC HEPATITIS; CLINICAL STAGING; HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; CLINICAL LABORATORY TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MASS SCREENING; MIDDLE AGED; PLATELET COUNT; SERUM; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 84879652821     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit245     Document Type: Article

References (31)

1. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicenter retrospective study on 68,276 biopsies. J Hepatol 1986; 2:165-73.
2. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-8.
3. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-57.
4. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterol 2012; 142:1293-302.
5. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol 2003; 38:518-26.
6. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase- to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology 2007; 46:912-21.
7. Lin Z-H, Xin Y-N, Dong Q-J, et al. Performance of the aspartate aminotransferase- to-platelet ration index for staging of hepatitis C-related fibrosis: An updated meta-analysis. Hepatol 2011; 53:726-36.
8. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, SánchezÁvila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7:350-7.
9. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
10. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology 2007; 46:32-6.
11. Adler M, Gulbis B, Moreno C, et al. The predictive value of FIB-4 versus Fibrotest, APRI, Fibroindex and Forn Index to non-invasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008; 47:762-3.
12. Boursier J, de Ledinghen V, Zarski J-P, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatol 2012; 55:58-67.
13. Poynard T, Ngo Y, Perazzo H, et al. Prognostic value of liver fibrosis biomarkers: A meta-analysis. Gastroenterol Hepatol 2011; 7:445-54.
14. Sebastiani G, Castera L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of noninvasive fibrosis biomarkers: An international study of 2411 cases. Aliment Pharmacol Ther 2011; 34:1202-16.
15. Chon YE, Jung ES, Park JY, et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol 2012; 46:518-25.
16. Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessment in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon 2012; 12:177-84.
17. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012; 55:1047-55.
18. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study ('CHeCS'). Clin Infect Dis 2013; 56:40-50.
19. Gara N, Zhao X, Kleiner DE, Liang J, Hoofnagle JH, Ghany M. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11:303-8.
20. Ghany MC, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49:1335-74.
21. Ghany MC, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on the treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
22. Mummadi RR, Petersen JR, Xiao S-Y, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010; 16:5710-5.
23. Seeff LB. The history of the "natural history" of hepatitis C (1968- 2009). Liver Int 2009; 29(s1):89-99.
24. Sanyal AJ. How to close the gap between the numbers of patients who need liver care and the providers available. American Association for the Study of Liver Diseases (AASLD) eNews 2010. Available at: http://www.aasld.org/news/ archive/022510/Pages/default.aspx Accessed 22 February 2013.
25. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment - Extension for Community Healthcare Outcomes (ECHO) Project: disruptive innovatioin in specialty care. Hepatology 2010; 52:1124-33.
26. Ryder SD, on behalf of the Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53:451-5.
27. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-32.
28. Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int 2012; 32:622-8.
29. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. Hepatology 2010; 51:828-35.
30. Meracke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009; 29:1500-6.
31. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14.